Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
比较拟上市的帕妥珠单抗生物类似药P013与参考产品在HER2阳性乳腺癌患者中的疗效和安全性:一项随机、III期等效性临床试验
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-09895-5
Allahyari, Abolghasem; Ehsanpour, Ali; Najafi, Behrouz; Ansarinejad, Nafiseh; Mehrzad, Valiollah; Kalantari, Behjat; Raafat, Jahangir; Ghadiany, Mojtaba; Shahi, Farhad; Gharib, Behrooz; Moazed, Vahid; Khosravi, Adnan; Mirpour, Mir Hossein; Salari, Sina; Mortazavizadeh, Seyedmohammadreza; Nekoyi, Amirabbas; Khani, Mohsen; Sadeghi, Alireza; Gharib, Sirus; Bary, Alireza; Mirzania, Mehrzad; Haghighat, Shirin; Razavi, Seyed Mohsen; Emami, Seyed Amir Hossein; Hosseinzadeh, Mehran; Mirbolouk, Mahdi; Sadighi, Sanambar; Shahrasbi, Abdolali; Esfahani, Ali; Gity, Masoumeh; Anjidani, Nassim; Kafi, Hamidreza; Najafi, Safa